Therapeutic potential of sh-vcyclin. (A) Bar chart shows the weight gain of 8 normal mice (weight control, ▪), 15 mice inoculated with 1 × 107 JSC1 cells (tumor only, ▩ ), 15 mice treated from day 3 after inoculation with 1 × 107 JSC-1 cells with sh-vcyclin (sh-vcyclin, □), or 15 mice treated from day 3 after inoculation with 1 × 107 JSC-1 cells with empty vector (empty vector, ▦). Treatment regime was 1 × 1010 293t IU of lentiviral vector on day 3 and 5 and then 1 × 109 293t IU lentiviral vector 3 times per week until day 14. (B) Kaplan-Meier survival curve shows a significant difference (P =.004) in survival between the empty vector (solid line) and the sh-vcyclin (gray line) groups. There was no significant difference (P = .4) between the tumor only (broken line) and empty vector groups. (C) Bar chart shows percent of mice ascites-free up to 5 weeks after injection of JSC-1 cells. Mice culled for reasons other than ascites are considered ascites-free. Bar shading is as in panel A. Error bars indicate the standard error of the mean.
